Answer- B
Cipla, a well-known Indian pharmaceutical enterprise, has declared that it has finalized a licensing contract with Novartis Pharma AG (Switzerland) to manufacture and distribute the Galvus series of drugs, employed for managing type 2 diabetes. The agreement is scheduled to take effect on January 1, 2026.